현재 위치
Home
산업원천기술개발사업 성과발표회 : 좌장: 김승욱 교수(고려대학교)
Development of Fc fusion protein for autoimmune disease using IL-23 antagonist
-
- 발행기관
- 한국생물공학회 바로가기
-
- 간행물
- 한국생물공학회 학술대회 바로가기
-
- 통권
- 2009 추계학술대회 및 국제심포지움 (2009.11)바로가기
-
- 페이지
- pp.114-114
-
- 저자
-
- 언어
- 영어(ENG)
-
- URL
- https://www.earticle.net/Article/A114489
※ 원문제공기관과의 협약기간이 종료되어 열람이 제한될 수 있습니다.
원문정보
초록
- 영어
- A p40-hyFc is a Fc fusion protein consisting of human p40 (a member of IL-12 family) and hybrid Fc (hyFc) derived from human IgD and IgG4 Fc regions. The p40 has been well known as a natural antagonist of IL-12 and IL-23 (1). Recently, it was reported that Th17 cell is a main regulator for autoimmune diseases and expanded by IL-23 (2), suggesting that the blockage of IL-23 signaling by long-acting p40 protein could be new approach to treat autoimmune diseases. The human p40-hyFc was demonstrated to specifically block IL-23 signaling in PBMCs from rheumatoid arthritis patients and mouse p40-hyFc (derivative of human p40-hyFc) also inhibited IL-23-mediated signaling in vitro and could decrease arthritis index score in mice collagen-induced arthritis (CIA) model In PK analysis using three cynomolgus monkeys, single subcutaneous injection with human p40-hyFc showed long half-life in monkeys. There was no significant increase in CBC and lymphocytes and no detectable Ab responses against human p40-hyFc. In cross-reactivity test, the human p40-hyFc did not show cross-reactivity with rodent, but did with monkeys. Therefore, the rhesus monkey model of CIA is the only available option to evaluate the efficacy of IL-12p40-hyFc in vivo. At present, the efficacy of human p40-hyFc was being evaluated in monkey CIA model in Nertherland primate center. To perform preclinical study, a stable cell line expressing human p40-hyFc was established, then MCB/WCB manufacturing and their characterizations are being conducted in Apptec company in USA. The process development for cultivation, purification, and analysis for p40-hyFc has been
performed during this study. Since there are non-responders to commercially available drugs such as Enbrel (TNFR-Fc) and Orencia (CTLA-4-Fc) targeting to soluble TNF- and CTLA4, respectively, human p40-hyFc could be a novel drug with different action mechanism and be used in combination with these therapeutics for patients.
저자
간행물 정보
발행기관
-
- 발행기관명
- 한국생물공학회 [The Korean Society for Biotechnology and Bioengineering]
- 설립연도
- 1984
- 분야
- 공학>생물공학
- 소개
- 이 법인은 생물 공학의 발전과 보급에 이바지하고, 회원 상호 간의 연구 협력과 친목을 도모함을 목적으로 한다 1. 생물공학 분야의 발전을 위한 연구 협력 2. 생물공학의 실용화를 촉진시키기 위한 산학 협동 3. 학술연구 발표회, 강연회, 연수회 등 학술활동의 개최 4. 국,영문 학술지,소식지,학술회의 Proceedings 및 학술도서의 발간 5. 생물공학 발전을 위한 정책 건의 6. 기타 국제 교류 등 본 학회의 목적 달성을 위한 제반 활동
간행물
-
- 간행물명
- 한국생물공학회 학술대회
- 간기
- 반년간
- 수록기간
- 1985~2013
- 십진분류
- KDC 476 DDC 576
이 권호 내 다른 논문 / 한국생물공학회 학술대회 2009 추계학술대회 및 국제심포지움
피인용수 : 0건 (자료제공 : 네이버학술정보)
함께 이용한 논문 이 논문을 다운로드한 분들이 이용한 다른 논문입니다.
출처 : 네이버학술정보
0개의 논문이 장바구니에 담겼습니다.